Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Resistant case of pCML

  • Giuseppe Saglio
  • Giuseppe Saglio's Avatar Topic Author
1 day 17 hours ago #2109 by Giuseppe Saglio
Replied by Giuseppe Saglio on topic Resistant case of pCML
Although a certain degree of response has been observed, it has not been optimal. Therefore, the chances of achieving an optimal response in future that would enable us to consider TFR are very limited. Given the present results and the low mortality associated with allotransplantation nowadays, I would opt if possible for this option rather than continuing with TKI therapy, given the uncertainty surrounding its results and the long-term toxicity.
  • Michael Mauro
  • Michael Mauro's Avatar Topic Author
1 day 8 hours ago #2110 by Michael Mauro
Replied by Michael Mauro on topic Resistant case of pCML
I agree with the thoughts of others- that any CML case such as this, allografting is a consideration when the patient is younger and fit and a donor is available, as there has not been a protective remission (MMR) established. In the pediatric cases as i know allografting is favored even earlier as later line therapies are not as developed and the risk/benefit may be more favourable. I agree with the lean away from the venetoclax; I agree with the lean towards access to asciminib (or potentially ponatinib, in that order) once dasatinib dose was exhausted. Best wishes to this young CML warrior...
Moderators: Nicolaarlene